CoLucid Pharmaceuticals Company Profile (NASDAQ:CLCD)

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLCD
  • CUSIP:
Key Metrics:
  • Previous Close: $38.15
  • 50 Day Moving Average: $18.82
  • 200 Day Moving Average: $10.13
  • 52-Week Range: $3.60 - $39.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.89
  • P/E Growth: 0.00
  • Market Cap: $584.99M
  • Outstanding Shares: 15,334,000
  • Beta: 1.83
Profitability:
  • Return on Equity: -85.68%
  • Return on Assets: -75.70%
Debt:
  • Current Ratio: 7.15%
  • Quick Ratio: 7.15%
Additional Links:
Companies Related to CoLucid Pharmaceuticals:

Analyst Ratings

Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.50 (3.54% upside)

Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
DateFirmActionRatingPrice TargetDetails
9/30/2016Piper Jaffray Cos.Boost Price TargetOverweight$36.00 -> $49.00View Rating Details
9/19/2016Ladenburg ThalmannSet Price TargetBuy$57.00View Rating Details
9/19/2016Stifel NicolausBoost Price TargetBuy$27.00 -> $30.00View Rating Details
11/10/2015William BlairInitiated CoverageBuy$22.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/10/2016Q2($0.84)($1.06)ViewN/AView Earnings Details
5/11/2016Q1($0.73)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details
8/12/2015($0.35)($1.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Current Year EPS Consensus Estimate: $-3.91 EPS
Next Year EPS Consensus Estimate: $-2.96 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.92)($0.92)($0.92)
Q4 20161($0.97)($0.97)($0.97)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 30.47%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2016Thomas P MathersCEOSell6,000$23.32$139,920.00View SEC Filing  
9/9/2016A/S NovoMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
9/7/2016Thomas P MathersCEOSell6,502$21.72$141,223.44View SEC Filing  
9/6/2016Linda C HoganInsiderSell48,736$19.87$968,384.32View SEC Filing  
8/31/2016Raymond SkwierczynskiInsiderSell150$10.86$1,629.00View SEC Filing  
8/19/2016Raymond SkwierczynskiInsiderSell508$8.41$4,272.28View SEC Filing  
8/10/2016Raymond SkwierczynskiInsiderSell508$8.30$4,216.40View SEC Filing  
8/5/2016Thomas P MathersCEOSell1,502$8.31$12,481.62View SEC Filing  
8/3/2016Domain Partners Vi, L.P.Major ShareholderSell153,028$8.45$1,293,086.60View SEC Filing  
7/29/2016Raymond SkwierczynskiInsiderSell508$9.09$4,617.72View SEC Filing  
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.76View SEC Filing  
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.80View SEC Filing  
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.16View SEC Filing  
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50View SEC Filing  
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateHeadline
thestreet.com logo4 Stocks with Strong Technicals to Buy Now (NASDAQ:CLCD)
www.thestreet.com - September 29 at 4:08 PM
News IconCoLucid Pharmaceuticals, Inc. (CLCD) Analyst Review - NewsDen (NASDAQ:CLCD)
newsden.net - September 28 at 9:06 AM
News IconIntraday Active Biotech Stocks News: CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), Juno Therapeutics Inc ... - The Voice Registrar (NASDAQ:CLCD)
voiceregistrar.com - September 26 at 4:29 PM
News IconCoLucid Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference - EconoTimes (NASDAQ:CLCD)
www.econotimes.com - September 26 at 9:00 AM
finance.yahoo.com logoCoLucid Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:CLCD)
finance.yahoo.com - September 26 at 9:00 AM
News IconTop Biotechnology Stock Picking: Zafgen, Inc. (ZFGN), CoLucid Pharmaceuticals, Inc. (CLCD) - The Independent Republic (NASDAQ:CLCD)
theindependentrepublic.com - September 23 at 9:23 AM
News IconTime To Put On The Watch List? - CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), Seres Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CLCD)
voiceregistrar.com - September 23 at 9:23 AM
News IconActive Stocks in 'How' and 'Why'- Applied Materials (AMAT), CoLucid Pharmaceuticals (CLCD), Marathon Patent (MARA) - Seneca Globe (NASDAQ:CLCD)
www.senecaglobe.com - September 21 at 8:17 AM
streetinsider.com logoCoLucid Pharmaceuticals (CLCD) Offers Interim Update on Lasmiditan Phase 3 (NASDAQ:CLCD)
www.streetinsider.com - September 19 at 5:01 PM
publicnow.com logoCORRECTING and REPLACING – CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR (NASDAQ:CLCD)
www.publicnow.com - September 19 at 5:01 PM
4-traders.com logoCoLucid Pharmaceuticals : Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday (NASDAQ:CLCD)
www.4-traders.com - September 19 at 8:58 AM
publicnow.com logoCoLucid Pharmaceuticals Provides Interim Update on GLADIATOR (NASDAQ:CLCD)
www.publicnow.com - September 19 at 8:58 AM
publicnow.com logoCoLucid Pharmaceuticals Announces Achievement of Secondary Endpoints in SAMURAI (NASDAQ:CLCD)
www.publicnow.com - September 17 at 9:00 AM
News IconCoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) EPS Analysis - Newburg Press (NASDAQ:CLCD)
newburghpress.com - September 16 at 4:09 PM
finance.yahoo.com logoCoLucid Pharmaceuticals (CLCD) is Overbought: Is A Drop Coming? (NASDAQ:CLCD)
finance.yahoo.com - September 16 at 4:09 PM
fool.com logoWhy CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday (NASDAQ:CLCD)
www.fool.com - September 15 at 5:17 PM
News IconAerie Pharmaceuticals Inc. (AERI) Has Surged To A New High On Study Results (NASDAQ:CLCD)
www.onenewspage.com - September 15 at 10:52 AM
News IconShares Climbing Higher Session: CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Post News (NASDAQ:CLCD)
www.kentuckypostnews.com - September 14 at 9:30 PM
News IconHC Stocks Overview= CoLucid Pharmaceuticals Inc (NASDAQ ... - share market updates (press release) (NASDAQ:CLCD)
sharemarketupdates.com - September 13 at 9:04 AM
News IconAnalysts Crunch in Focus- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), Brookdale Senior Living Inc. (NYSE:BKD) - Seneca Globe (NASDAQ:CLCD)
www.senecaglobe.com - September 10 at 4:02 PM
finance.yahoo.com logo9:16 am CoLucid Pharmaceuticals prices its 3.25 mln share underwritten public offering of common stock at $20.00/share for gross proceeds of $65 mln (NASDAQ:CLCD)
finance.yahoo.com - September 10 at 4:02 PM
biz.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Ex (NASDAQ:CLCD)
biz.yahoo.com - September 10 at 8:54 AM
News IconBiotech Stocks Worth Chasing: CoLucid Pharmaceuticals, Inc ... - National Daily Press (NASDAQ:CLCD)
www.nationaldailypress.com - September 9 at 4:07 PM
publicnow.com logoCoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock (NASDAQ:CLCD)
www.publicnow.com - September 9 at 4:07 PM
thestreet.com logoHere's a Reason Why CoLucid Pharmaceuticals (CLCD) Stock Is Higher Today (NASDAQ:CLCD)
www.thestreet.com - September 9 at 4:07 PM
News IconIntraday Movers: Sempra Energy (NYSE:SRE), Peregrine Pharmaceuticals (NASDAQ:PPHM), CoLucid ... - NYSE Journal (press release) (NASDAQ:CLCD)
stockznews.com - September 9 at 9:04 AM
News IconConsensus Take: CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:CLCD)
friscofastball.com - September 9 at 9:04 AM
streetinsider.com logoCoLucid Pharmaceuticals (CLCD) to Offer Common Shares - StreetInsider.com (NASDAQ:CLCD)
www.streetinsider.com - September 9 at 9:04 AM
News IconCoLucid Pharmaceuticals Announces Proposed Public Offering of Common Stock - EconoTimes (NASDAQ:CLCD)
www.econotimes.com - September 8 at 4:07 PM
News IconShares Gapping Lower Before the Open: CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Post News (NASDAQ:CLCD)
www.kentuckypostnews.com - September 8 at 4:07 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces Proposed Public Offering of Common Stock (NASDAQ:CLCD)
finance.yahoo.com - September 8 at 4:07 PM
News Icon$CLCD & $GBSN - CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) & Great Basin Scientific Inc (NASDAQ:GBSN ... - Money News (NASDAQ:CLCD)
www.newsismoney.com - September 8 at 5:25 AM
istreetwire.com logoTrader Alert: CoLucid Pharmaceuticals, Inc. (CLCD), Kinder Morgan, Inc. (KMI), Activision Blizzard, Inc. (ATVI) - iStreetWire (NASDAQ:CLCD)
istreetwire.com - September 7 at 4:16 PM
News IconStocks Gainers/Losers Roundup- CoLucid Pharmaceuticals (CLCD), Karyopharm Therapeutics (KPTI), Tonix ... - Seneca Globe (NASDAQ:CLCD)
www.senecaglobe.com - September 7 at 4:16 PM
News IconShares Moving Down in Trade: CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Post News (NASDAQ:CLCD)
www.kentuckypostnews.com - September 7 at 4:16 PM
publicnow.com logoCoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine (NASDAQ:CLCD)
www.publicnow.com - September 6 at 4:07 PM
thestreet.com logoCoLucid Pharmaceuticals (CLCD) Stock Skyrockets on Migraine Drug Trial Success (NASDAQ:CLCD)
www.thestreet.com - September 6 at 4:07 PM
insidermonkey.com logoCoLucid Pharmaceuticals Inc (CLCD): What The Data Means (NASDAQ:CLCD)
www.insidermonkey.com - September 6 at 4:07 PM
rttnews.com logoWill SAMURAI Spell Relief For CoLucid Investors? (NASDAQ:CLCD)
www.rttnews.com - September 6 at 9:06 AM
streetinsider.com logoCoLucid Pharmaceuticals' (CLCD) SAMURAI Phase 3 Trial of Lasmiditan in Migraine Meets Primary and Secondary Endpoints (NASDAQ:CLCD)
www.streetinsider.com - September 6 at 9:06 AM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces Achievement of Both Primary and Key ... (NASDAQ:CLCD)
finance.yahoo.com - September 6 at 9:06 AM
marketexclusive.com logoTwo Catlaysts To Watch Early September In Biotech: Bioline RX Ltd (NASDAQ:BLRX) and CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) (NASDAQ:CLCD)
marketexclusive.com - August 25 at 9:10 AM
finance.yahoo.com logoKing Fish Media Announces Website Launch for CoLucid Pharmaceuticals (NASDAQ:CLCD)
finance.yahoo.com - August 18 at 11:21 AM
cnbc.com logoCoLucid Pharmaceuticals posts 2Q loss (NASDAQ:CLCD)
www.cnbc.com - August 10 at 10:28 PM
publicnow.com logoCoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights (NASDAQ:CLCD)
www.publicnow.com - August 10 at 4:19 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting in New York City (NASDAQ:CLCD)
finance.yahoo.com - June 22 at 4:01 PM
capitalcube.com logoCoLucid Pharmaceuticals, Inc. :CLCD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:CLCD)
www.capitalcube.com - June 8 at 6:04 PM
publicnow.com logoCoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine (NASDAQ:CLCD)
www.publicnow.com - June 7 at 8:48 AM
finance.yahoo.com logoCoLucid Pharmaceuticals to Participate at the Jefferies 2016 Healthcare Conference (NASDAQ:CLCD)
finance.yahoo.com - June 2 at 8:58 AM
finance.yahoo.com logoCoLucid Pharmaceuticals (CLCD) in Focus: Stock Rises 11.1% (NASDAQ:CLCD)
finance.yahoo.com - June 1 at 8:15 AM

Social

CoLucid Pharmaceuticals (NASDAQ:CLCD) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff